Which country is ivonib/ivitinib from?

Ivosidenib/Ivosidenib is a small molecule oral drug developed by Agios Pharmaceuticals in the United States. It is mainly used to treat cancer patients with IDH1 gene mutations. The IDH1 enzyme plays an important role in cell metabolism and is responsible for catalyzing the conversion of isocitrate into α-ketoglutarate. It also participates in the reduction reaction of NADP to generate NADPH. Under normal circumstances, this process is critical to maintaining the cell's energy metabolism and antioxidant capacity. However, when the IDH1 gene is mutated, the function of the enzyme is altered, resulting in excessive production of the metabolite D-2-glutarate (2-HG). This metabolite is believed to play an important role in the occurrence and development of various cancers, including acute myeloid leukemia (AML), cholangiocarcinoma, and myelodysplastic syndromes.

The accumulation of 2-HG can interfere with the normal metabolism and epigenetic regulation of cells, thereby promoting the occurrence of tumors. The mechanism of ivonib is to inhibit the mutated IDH1 enzyme, thereby reducing the level of 2-HG and restoring normal cell metabolism. This treatment strategy provides a new option for traditional chemotherapy and radiotherapy, especially for patients who do not respond to or develop resistance to conventional treatments. Clinical trial results show that ivonib has shown good efficacy in the treatment of acute myeloid leukemia patients with IDH1 mutations, bringing hope to the patients' survival.

The dose of ivonib is usually set at 500 mg daily, which can be taken with or without food. Patients need to continue taking it until disease progression or unacceptable side effects occur. With the approval of the FDA, ivonib has become one of the important drugs in the clinical treatment of specific types of cancer. Due to the targeted nature of the drug, doctors will use genetic testing to ensure that the patient has an IDH1 mutation before use to guide the treatment plan.